Cited by 1,059Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Open access

Turke, Alexa B., Zejnullahu, Kreshnik, Wu, Yi-Long, Song, Youngchul, Dias-Santagata, Dora, Lifshits, Eugene, Toschi, Luca, Rogers, Andrew, Mok, Tony, Sequist, Lecia, Lindeman, Neal I., Murphy, Carly, Akhavanfard, Sara, Yeap, Beow Y., Xiao, Yun, Capelletti, Marzia, Iafrate, A. John, Lee, Charles, Christensen, James G., Engelman, Jeffrey A., Jänne, Pasi A.·2010·Cancer Cell

DOI 10.1016/j.ccr.2009.11.022PMC PMC2980857

Open this paper in CoChat — free account Open PDF

Abstract

MET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung cancers and causes resistance to EGFR kinase inhibitors. We demonstrate that MET activation by its ligand, HGF, also induces drug resistance, but through GAB1 signaling. Using high-throughput FISH analyses in both cell lines and in patients with lung cancer, we identify subpopulations of cells with MET amplification prior to drug exposure. Surprisingly, HGF accelerates the development of MET amplification both in vitro and in vivo. EGFR kinase inhibitor resistance, due to either MET amplification or autocrine HGF production, was cured in vivo by combined EGFR and MET inhibition. These findings highlight the potential to prospectively identify treatment naive, patients with EGFR-mutant lung cancer who will benefit from initial combination therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2009.11.022

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citation
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“Secondary mutations in EGFR itself, including the EGFR T790M ‘‘gatekeeper’’ mutation is observed in 50% of resistance cases, and amplification of the MET oncogene is observed in 20% of resistance cases (Balak et al., 2006; Bean et al., 2007; Engelman et al., 2007b; Kobayashi et al., 2005; Kosaka et al., 2006; Pao et a…”
Background
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 2×
“To date, resistance mechanisms have predominately involved secondary genomic alterations in the target kinase that alter either the physical (such as steric hindrance) or biochemical (change in ATP affinity) properties of the receptor and result in drug resistance (Gorre et al., 2001; Shah et al., 2002; Yun et al., 20…”
Background
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Self-citation

Flagged first, then by citations

Show all 37 references

Sorted by citations

Items 201–300 of 1,000

Phenotypic Plasticity, Bet-Hedging, and Androgen Independence in Prostate Cancer: Role of Non-Genetic Heterogeneity
Jolly, M. K., Kulkarni, P., Weninger, K., Orban, J. P., & Levine, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00050 · Cited by 116
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer
Camidge, D. R., Barlési, F., Goldman, J. W., Morgensztern, D., Heist, R. S., Vokes, E. E., Spira, A. I., Angevin, E., Su, W., Hong, D. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00739 · Cited by 117
HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors
Gusenbauer, S., Vlaicu, P., & Ullrich, A. (2012) · Oncogene · doi:10.1038/onc.2012.396 · Cited by 115
Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors
Smyth, E. C., Sclafani, F., & Cunningham, D. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s44941 · Cited by 115
Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET
Mitamura, T., Watari, H., Wang, L., Kanno, H., Hassan, M. K., Miyazaki, M., Katoh, Y., Kimura, T., Tanino, M. A., Nishihara, H., et al. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.3 · Cited by 114
SiCloneFit: Bayesian inference of population structure, genotype, and phylogeny of tumor clones from single-cell genome sequencing dataPreprint
Zafar, H., Navin, N. E., Chen, K., & Nakhleh, L. K. (2019) · Genome Research · doi:10.1101/gr.243121.118 · Cited by 113
Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non–Small-Cell Lung Cancer
Gadgeel, S. M., & Wozniak, A. J. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.12.001 · Cited by 116
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma
Stewart, E., Mascaux, C., Pham, N., Sakashita, S., Sykes, J. R., Kim, L., Yanagawa, N., Allo, G., Ishizawa, K., Wang, D. Y. Q., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.1492 · Cited by 112
Droplet-Based Digital PCR
Perkins, G., Lu, H., Garlan, F., & Taly, V. (2016) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.10.001 · Cited by 114
Urinary exosomes-based Engineered Nanovectors for Homologously Targeted Chemo-Chemodynamic Prostate Cancer Therapy via abrogating EGFR/AKT/NF-kB/IkB signaling
Pan, S., Zhang, Y., Huang, M., Deng, Z., Zhang, A., Pei, L., Wang, L., Zhao, W., Ma, L., Zhang, Q., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120946 · Cited by 116
Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met
Mueller, K. L., Madden, J. M., Zoratti, G. L., Kuperwasser, C., List, K., & Boerner, J. L. (2012) · Breast Cancer Research · doi:10.1186/bcr3224 · Cited by 112
Bispecific antibodies in cancer therapy: Target selection and regulatory requirements
Sun, Y., Yu, X., Wang, X., Yuan, K., Wang, G., Hu, L., Zhang, G., Pei, W., Wang, L., Sun, C., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.023 · Cited by 116
BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications
Oikonomou, E., Koustas, E., Goulielmaki, M., & Pintzas, A. (2014) · Oncotarget · doi:10.18632/oncotarget.2555 · Cited by 113
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
Noronha, A., Nataraj, N. B., Lee, J. S., Zhitomirsky, B., Oren, Y., Oster, S. K., Lindzen, M., Mukherjee, S., Will, R. D., Ghosh, S., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0111 · Cited by 113
Cancer in Light of Experimental Evolution
Sprouffske, K., Merlo, L. M. F., Gerrish, P. J., Maley, C. C., & Sniegowski, P. (2012) · Current Biology · doi:10.1016/j.cub.2012.06.065 · Cited by 110
Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth
Harbinski, F., Craig, V. J., Sanghavi, S., Jeffery, D. A., Liu, L., Sheppard, K. A., Wagner, S., Stamm, C., Buneß, A., Chatenay‐Rivauday, C., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0237 · Cited by 107
Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance
Boeckx, C., Baay, M. F. D., Wouters, A., Specenier, P. M., Vermorken, J. B., Peeters, M., & Lardon, F. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0013 · Cited by 110
Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer
Donev, I. S., Wang, W., Yamada, T., Li, Q., Takeuchi, S., Matsumoto, K., Yamori, T., Nishioka, Y., Sone, S., & Yano, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1993 · Cited by 111
PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data
Piñeiro-Yáñez, E., Reboiro‐Jato, M., Goméz-López, G., Perales-Patón, J., Troulé, K., Rodrı́guez, J. M., Tejero, H., Shimamura, T., Lopez-Casas, P. P., Carretero, J., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0546-1 · Cited by 104
Heterogeneity in Cancer
MacDonald, W., Purcell, C., Pinho-Schwermann, M. P., Stubbs, N. M., Srinivasan, P. R., & El‐Deiry, W. S. (2025) · Cancers · doi:10.3390/cancers17030441 · Cited by 119
Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET
Xu, L., Kikuchi, E., Xu, C., Ebi, H., Ercan, D., Cheng, K. A., Padera, R. F., Engelman, J. A., Janne, P. A., Shapiro, G. I., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3720 · Cited by 106
Self-citation
Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer
Beckman, R. A., Schemmann, G. S., & Yeang, C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203559109 · Cited by 106
Curcumin: Updated Molecular Mechanisms and Intervention Targets in Human Lung Cancer
Ye, M.-X., Li, Y., Yin, H., & Zhang, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13033959 · Cited by 108
MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF -Mutated Colorectal Cancer
Pietrantonio, F., Oddo, D., Gloghini, A., Valtorta, E., Berenato, R., Barault, L., Caporale, M., Busico, A., Morano, F., Gualeni, A. V., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0297 · Cited by 103
20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight
Singh, S. K., Sadhukhan, S., & Sonawane, A. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188967 · Cited by 109
The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies
Greulich, H. E. (2010) · Genes & Cancer · doi:10.1177/1947601911407324 · Cited by 109
Insight into the Role of Wnt5a-Induced Signaling in Normal and Cancer Cells
Endo, M., Nishita, M., Fujii, M., & Minami, Y. (2014) · International review of cytology · doi:10.1016/bs.ircmb.2014.10.003 · Cited by 103
Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation
Braun, C. J., Bruno, P. M., Horlbeck, M. A., Gilbert, L. A., Weissman, J. S., & Hemann, M. T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600582113 · Cited by 104
Imaging Phenotypes of Breast Cancer Heterogeneity in Preoperative Breast Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) Scans Predict 10-Year Recurrence
Chitalia, R., Rowland, J., McDonald, E. S., Pantalone, L., Cohen, E. A., Gastounioti, A., Feldman, M. D., Schnall, M. D., Conant, E. F., & Despina Kontos, B. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4067 · Cited by 102
Understanding resistance to combination chemotherapy
Pritchard, J. R., Lauffenburger, D. A., & Hemann, M. T. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.10.003 · Cited by 100
Personalized medicine for lung cancer: new challenges for pathology
Kerr, K. M. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.03854.x · Cited by 104
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours
Crucitta, S., Cucchiara, F., Mathijssen, R. H. J., Mateo, J., Jager, A., Joosse, A., Passaro, A., Attili, I., Petrini, I., van Schaik, R. H., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102340 · Cited by 106
Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
Neel, D. S., & Bivona, T. G. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0007-0 · Cited by 98
ADAM-10 and -17 regulate endometriotic cell migration via concerted ligand and receptor shedding feedback on kinase signaling
Miller, M. A., Meyer, A. S., Beste, M. T., Lasisi, Z., Reddy, S., Jeng, K., Chen, C., Han, J., Isaacson, K., Griffith, L. G., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222387110 · Cited by 96
EGFR mutations in lung cancer: from tissue testing to liquid biopsy
Fenizia, F., Luca, A. D., Pasquale, R., Sacco, A., Forgione, L., Lambiase, M., Iannaccone, A., Chicchinelli, N., Franco, R., Rossi, A., et al. (2015) · Future Oncology · doi:10.2217/fon.15.23 · Cited by 95
Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
Findlay, J. M., Castro-Giner, F., Makino, S., Rayner, E., Kartsonaki, C., Cross, W. C. H., Kovac, M. B., Ulahannan, D., Palles, C., Gillies, R. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms11111 · Cited by 97
A New View of Pathway-Driven Drug Resistance in Tumor Proliferation
Nussinov, R., Tsai, C., & Jang, H. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.02.001 · Cited by 94
Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors
Dorsch, D., Schadt, O., Stieber, F., Meyring, M., Grädler, U., Bladt, F., Friese‐Hamim, M., Knuehl, C., Pehl, U., & Blaukat, A. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.02.002 · Cited by 93
Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
Datta, J., Damodaran, S., Parks, H., Ocrainiciuc, C., Miya, J., Yu, L., Gardner, E. P., Samorodnitsky, E., Wing, M. R., Bhatt, D., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-1010 · Cited by 93
Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer
Chhouri, H., Alexandre, D., & Grumolato, L. (2023) · Cancers · doi:10.3390/cancers15020504 · Cited by 103
Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme
Jun, H. J., Acquaviva, J., Chi, D., Lessard, J., Zhu, H., Woolfenden, S., Bronson, R. T., Pfannl, R., White, F., Housman, D. E., et al. (2011) · Oncogene · doi:10.1038/onc.2011.474 · Cited by 94
Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas
Looyenga, B. D., Furge, K. A., Dykema, K. J., Koeman, J. M., Swiatek, P. J., Giordano, T. J., West, A. B., Resau, J. H., Teh, B. T., & MacKeigan, J. P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012500108 · Cited by 99
S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
Burbridge, M. F., Bossard, C. J., Saunier, C., Fejes, I., Bruno, A., Léonce, S., Ferry, G., Violante, G. D., Bouzom, F., Cattan, V., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0075 · Cited by 94
Cell-Autonomous and Non–Cell-Autonomous Mechanisms of HGF/MET–Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective
Corso, S., & Giordano, S. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0040 · Cited by 96
Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics
Stella, G. M., Luisetti, M., Pozzi, E., & Comoglio, P. M. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70009-2 · Cited by 90
ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1
Yamaguchi, T., Lu, C., Ida, L., Yanagisawa, K., Usukura, J., Cheng, J., Hotta, N., Shimada, Y., Isomura, H., Suzuki, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms10060 · Cited by 91
Molecular Profiling: Moving Away from Tumor Philately
Reis-Filho, J. S., Weigelt, B., Fumagalli, D., & Sotiriou, C. P. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001329 · Cited by 90
Tumor heterogeneity and circulating tumor cells
Zhang, C., Guan, Y., Sun, Y., Ai, D., & Guo, Q. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.024 · Cited by 90
Mechanisms of acquired resistance to tyrosine kinase inhibitors
Chen, Y., & Fu, L. (2011) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2011.10.007 · Cited by 89
The dynamic nature of the kinome
Graves, L. M., Duncan, J. S., Whittle, M. C., & Johnson, G. L. (2013) · Biochemical Journal · doi:10.1042/bj20121456 · Cited by 93
Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer
Huw, L.-Y., O'Brien, C. L., Pandita, A., Mohan, S., Spoerke, J. M., Lu, S., Wang, Y., Hampton, G. M., Wilson, T. R., & Lackner, M. R. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.46 · Cited by 90
Targeted therapies for squamous cell carcinoma of the head and neck: Current knowledge and future directions
Schmitz, S., Ang, K. K., Vermorken, J. B., Haddad, R. I., Suarez, C. M., Wolf, G. T., Hamoir, M., & Machiels, J.-P. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.09.007 · Cited by 88
Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
Goffin, J. R., & Zbuk, K. M. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.08.007 · Cited by 88
Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)
Murakami, H., Tamura, T., Takahashi, T., Nokihara, H., Naito, T., Nakamura, Y., Nishio, K., Seki, Y., Sarashina, A., Shahidi, M., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1738-1 · Cited by 88
c-Met and Other Cell Surface Molecules: Interaction, Activation and Functional Consequences
Viticchiè, G., & Muller, P. A. J. (2015) · Biomedicines · doi:10.3390/biomedicines3010046 · Cited by 88
Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
von Manstein, V., Yang, C., Richter, D. E., Delis, N., Vafaizadeh, V., & Groner, B. (2014) · Current Signal Transduction Therapy · doi:10.2174/1574362409666140206221931 · Cited by 88
Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
Grugan, K. D., Dorn, K., Jarantow, S. W., Bushey, B. S., Pardinas, J. R., Laquerre, S. G., Moores, S. L., & Chiu, M. L. (2016) · mAbs · doi:10.1080/19420862.2016.1249079 · Cited by 92
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer
Cascone, T., Xu, L., Lin, H. Y., Liu, W., Tran, H. T., Liu, Y., Howells, K., Haddad, V., Hanrahan, E. O., Nilsson, M. B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3216 · Cited by 92
Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?
Wu, Y.-L. L. C., Soo, R. A., Locatelli, G., Stammberger, U. M., Scagliotti, G. V., & Park, K. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.003 · Cited by 83
Self-citation
Dissecting Variability in Responses to Cancer Chemotherapy Through Systems Pharmacology
Yang, R., Niepel, M., Mitchison, T., & Sorger, P. K. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.96 · Cited by 86
Gastric cancer and the epoch of immunotherapy approaches
Niccolai, E., Taddei, A., Prisco, D., & Amedei, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i19.5778 · Cited by 84
Tumor cell heterogeneity.
Chekhun, V. F., Sd, S., & Zd, S. (1985) · PubMed · Cited by 84
Compensatory Pathways in Oncogenic Kinase Signaling and Resistance to Targeted Therapies: Six Degrees of Separation
Trusolino, L., & Bertotti, A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0400 · Cited by 86
HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
Karagiannis, D., & Rampias, T. N. (2021) · Cancers · doi:10.3390/cancers13143575 · Cited by 88
Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer
Wang, W., Li, Q., Takeuchi, S., Yamada, T., Koizumi, H., Nakamura, T., Matsumoto, K., Mukaida, N., Nishioka, Y., Sone, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1171 · Cited by 86
Microenvironment-Derived HGF Overcomes Genetically Determined Sensitivity to Anti-MET Drugs
Pennacchietti, S., Cazzanti, M., Bertotti, A., Rideout, W. M., Han, M., Gyuris, J., Perera, T. P. S., Comoglio, P. M., Trusolino, L., & Michieli, P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0761 · Cited by 83
InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma
Ma, Y., Tang, N., Thompson, R. C., Mobley, B. C., Clark, S. W., Sarkaria, J. N., & Wang, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1677 · Cited by 84
MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING
Zhang, Y., Yang, Q., Zeng, X., Wang, M., Dong, S., Yang, B., Tu, X., Wei, T., Xie, W., Zhang, C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1500 · Cited by 82
Therapeutic and prognostic insights from the analysis of cancer mutational signatures
Brady, S. W., Gout, A. M., & Zhang, J. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.08.007 · Cited by 82
Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment
Li, J., Zhu, L., & Kwok, H. F. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100904 · Cited by 89
Dynamics of targeted cancer therapy
Božić, I., Allen, B., & Nowak, M. A. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.04.006 · Cited by 86
Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block
Jathal, M. K., Chen, L., Mudryj, M. M., & Ghosh, P. (2011) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152211795495643 · Cited by 80
Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy
Domvri, K., Zarogoulidis, P., Darwiche, K., Browning, R. F., Jr., Li, Q., Turner, J. F., Kioumis, I. P., Spyratos, D., Porpodis, Κ., Papaiwannou, A., et al. (2013) · Journal of Cancer · doi:10.7150/jca.7734 · Cited by 82
Hepatocyte growth factor and Met in drug discovery
Sakai, K., Aoki, S., & Matsumoto, K. (2015) · The Journal of Biochemistry · doi:10.1093/jb/mvv027 · Cited by 82
Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer
Cheng, N., Li, X., Zhao, C., Ren, S., Chen, X., CAI, W., Zhao, M., ZHANG, Y., LI, J., WANG, Q., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3643 · Cited by 81
Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR -Mutant Lung Cancer
Nakagawa, T., Takeuchi, S., Yamada, T., Nanjo, S., Ishikawa, D., Sano, T., Kita, K., Nakamura, T., Matsumoto, K., Suda, K., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0195 · Cited by 82
MET Kinase Inhibitor SGX523 Synergizes with Epidermal Growth Factor Receptor Inhibitor Erlotinib in a Hepatocyte Growth Factor–Dependent Fashion to Suppress Carcinoma Growth
Zhang, Y.-W., Staal, B., Essenburg, C. J., Su, Y., Kang, L., West, R. A., Kaufman, D. W., DeKoning, T., Eagleson, B., Buchanan, S. G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0898 · Cited by 80
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
Rolfo, C. D., Giovannetti, E., Hong, D. S., Bivona, T. G., Raez, L. E., Bronte, G., Buffoni, L., Reguart, N., Santos, E. S., Germonpré, P. R., et al. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.009 · Cited by 80
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma
Camidge, D. R., Morgensztern, D., Heist, R. S., Barve, M. A., Vokes, E. E., Goldman, J. W., Hong, D. S., Bauer, T. M., Strickler, J. H., Angevin, E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0765 · Cited by 83
Met Is the Most Frequently Amplified Gene in Endometriosis-Associated Ovarian Clear Cell Adenocarcinoma and Correlates with Worsened Prognosis
Yamashita, Y., Akatsuka, S., Shinjo, K., Yatabe, Y., Kobayashi, H., Seko, H., Kajiyama, H., Kikkawa, F., Takahashi, T., & Toyokuni, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057724 · Cited by 83
Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients
Lin, L., & Bivona, T. G. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/817297 · Cited by 85
Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
Nam, H.-J., Ching, K. A., Kan, J. L. C., Kim, H., Han, S., Im, S., Kim, T., Christensen, J. G., Oh, D., & Bang, Y. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0494 · Cited by 79
Self-citation
CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations
Guernet, A. A., Mungamuri, S. K., Cartier, D., Sachidanandam, R., Jayaprakash, A. D., Adriouch, S., Vézain, M., Charbonnier, F., Rohkin, G., Coutant, S., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.06.017 · Cited by 85
Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project
Bubendorf, L., Dafni, U. G., Schöbel, M., Finn, S. P., Tischler, V., Sejda, A., Marchetti, A., Thunnissen, E., Verbeken, E. K., Warth, A., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.021 · Cited by 79
Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives
Chen, H., & Cheng, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s66502 · Cited by 81
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
Re, M. D., Crucitta, S., Gianfilippo, G., Passaro, A., Petrini, I., Restante, G., Michelucci, A., Fogli, S., de Marinis, F., Porta, C., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163951 · Cited by 84
Understanding Drug Sensitivity and Tackling Resistance in Cancer
Tyner, J. W., Haderk, F., Kumaraswamy, A., Baughn, L. B., Ness, B. V., Liu, S., Marathe, H., Alumkal, J. J., Bivona, T. G., Chan, K. S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3695 · Cited by 81
Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma
Kasahara, K., Arao, T., Sakai, K., MATSUMOTO, K. Y., Sakai, A., Kimura, H., Sone, T., Horiike, A., Nishio, M., Ohira, T., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0383 · Cited by 77
Acquisition of cancer stem cell‐like properties in non‐small cell lung cancer with acquired resistance to afatinib
Hashida, S., Yamamoto, H., Shien, K., Miyoshi, Y., Ohtsuka, T., Suzawa, K., Watanabe, M., Maki, Y., Soh, J., Asano, H., et al. (2015) · Cancer Science · doi:10.1111/cas.12749 · Cited by 79
Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib
Goldman, J. W., Laux, I., Chai, F., Savage, R. E., Ferrari, D., Garmey, E. G., Just, R. G., & Rosen, L. S. (2012) · Cancer · doi:10.1002/cncr.27575 · Cited by 77
Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer
Dienstmann, R., Dosso, S. D., Felip, E., & Tabernero, J. M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.11.009 · Cited by 77
Targeting the MET gene for the treatment of non-small-cell lung cancer
Gelsomino, F., Facchinetti, F., Haspinger, E. R., Garassino, M. C., Trusolino, L., de Braud, F., & Tiseo, M. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.11.006 · Cited by 77
Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
Linklater, E. S., Tovar, E. A., Essenburg, C. J., Turner, L., Madaj, Z., Winn, M. E., Melnik, M. K., Körkaya, H., Maroun, C. R., Christensen, J. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12065 · Cited by 77
Self-citation
Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER-2+ Metastatic Breast Cancer
Wong, H., Leung, R. C.-Y., Kwong, A., Chiu, J. W. Y., Liang, R. H.-S., Swanton, C., & Yau, T. C. C. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0165 · Cited by 76
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR- Activating Mutation
Monica, S. L., Madeddu, D., Tiseo, M., Vivo, V., Galetti, M., Cretella, D., Bonelli, M. A., Fumarola, C., Cavazzoni, A., Falco, A., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.006 · Cited by 75
Cancer drug resistance: A fleet to conquer
Hussain, S., Singh, A., Nazir, S. U., Tulsyan, S., Khan, A., Kumar, R., Bashir, N., Tanwar, P., & Mehrotra, R. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28782 · Cited by 80
Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC)
Langer, C. J., Mok, T. S. K., & Postmus, P. E. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.05.003 · Cited by 75
Self-citation
New Strategies for Treatment of ALK-Rearranged Non–Small Cell Lung Cancers
Sasaki, T., & Janne, P. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1404 · Cited by 75
Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF V600E Colorectal Cancer
Hazar-Rethinam, M. H., Kleyman, M., Han, G. C., Liu, D., Ahronian, L. G., Shahzade, H. A., Chen, L., Parikh, A. R., Allen, J. N., Clark, J. W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1227 · Cited by 77
Self-citation
Oligosaccharyltransferase: A Gatekeeper of Health and Tumor Progression
Harada, Y., Ohkawa, Y., Kizuka, Y., & Taniguchi, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236074 · Cited by 76

Authors: Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., Lindeman, N. I., Murphy, C., Akhavanfard, S., Yeap, B. Y., Xiao, Y., Capelletti, M., Iafrate, A. J., Lee, C., Christensen, J. G., Engelman, J. A., & Jänne, P. A.
Affiliations: Harvard University (US)
Dana-Farber Cancer Institute (US)
Guangdong General Hospital (CN)
Massachusetts General Hospital (US)
Chinese University of Hong Kong (HK)
Brigham and Women's Hospital (US)
Pfizer (United States) (US)
Corresponding author: Engelman, Jeffrey A.
ORCID: Wu, Yi-Long
Song, Youngchul
Dias-Santagata, Dora
Toschi, Luca
Mok, Tony
Sequist, Lecia
Lindeman, Neal I.
Akhavanfard, Sara
Yeap, Beow Y.
Capelletti, Marzia
Iafrate, A. John
Lee, Charles
Christensen, James G.
Engelman, Jeffrey A.
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2010-01
Volume: 17
Issue: 1
Pages: 77-88
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2009.11.022
PMC: PMC2980857
OpenAlex: W1985264867
Cited by: 1,059
References: 37
Citations by year: 2026: 22 · 2025: 31 · 2024: 36 · 2023: 58 · 2022: 41 · 2021: 55 · 2020: 41 · 2019: 56 · 2018: 66 · 2017: 73 · 2016: 93 · 2015: 84 · 2014: 88 · 2013: 94 · 2012: 106
FWCI: 83.75
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1293 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Guangdong Provincial Hospital of Traditional Chinese Medicine
University of Hong Kong
Chinese University of Hong Kong
National Institutes of Health
National Cancer Institute (P50CA127003, R01CA140594, R01CA114465, P50CA090578, R01CA135257, K08CA120060, R01CA137008)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: MET amplification, EGFR mutation, non-small cell lung cancer, hepatocyte growth factor, clonal selection, combination therapy
MeSH terms: Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Gene Amplification, Humans, Lung Neoplasms, Mutation, Proto-Oncogene Proteins, Signal Transduction, Gene Expression, Polymerase Chain Reaction, Hepatocyte Growth Factor, In Situ Hybridization, Fluorescence, Receptors, Growth Factor, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Quinazolinones, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks